greeksoup/ stock research
Stock research / United States / TAK / Year to 31 March 2020

Takeda Pharmaceutical Company Limited (TAK) annual results, year to 31 March 2020: revenue JPY 3,291 billion, from the 20-F

Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2020 it reported revenue of JPY 3,291 billion ($30.3 billion at the year's average rate), up 56.9% on the year before. Its profit attributable to shareholders was JPY 44.2 billion, down 67.3%, and diluted earnings per share JPY 28.25.

Revenue
JPY 3,291 billion
+56.9% on the year
FY2017FY2020
Operating margin
3.1%
11.3% a year earlier
FY2017FY2020
Net income
JPY 44.2 billion
-67.3% on the year
FY2017FY2020
Diluted EPS
JPY 28.25
-79.8% on the year
FY2017FY2020

this yearthe year beforeIn yen as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2019 †Mar 2020
Revenue2,0973,291
Cost of sales6521,090
Research and development368492
Operating profit238100
Finance costs83.3165
Profit before tax128-60.8
Income tax-7.5-105
Profit for the year13544.3
Profit attributable to shareholders13544.2
Filing20-F20-F
JPY billion, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2019 †Mar 2020
Diluted EPS139.8228.25
Basic EPS140.6128.41
Filing20-F20-F

JPY per ordinary share, as filed.

Cash flow

Year toMar 2019 †Mar 2020
Cash from operations328670
Purchase of property, plant and equipment77.7127
Free cash flow251543
Cash from investing-2,836292
Cash from financing2,946-1,005
Depreciation and amortisation248584
Buybacks1.23.7
Dividends paid143283
Filing20-F20-F

JPY billion. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2019 †Mar 2020
Funded by
Equity attributable to shareholders5,1824,723
Non-controlling interests4.04.0
Borrowings, as filed5,7515,093
Lease liabilities0.0369
Other liabilities2,8562,631
Total equity and liabilities13,79312,821
Owned
Property, plant and equipment1,3321,386
Goodwill4,2404,013
Other intangible assets4,7514,171
Cash and cash equivalents702638
Trade and other receivables742757
Inventories920760
Other assets1,1061,097
Total assets13,79312,821
Filing20-F20-F

JPY billion, at each fiscal year end.

Ratios on the filed lines

Year toMar 2019 †Mar 2020
Operating margin11.3%3.1%
Net margin6.4%1.3%
Free cash flow margin12.0%16.5%
Return on year-end equity2.6%0.9%
Effective tax rate-5.9%n/a
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2020, filed 29 June 2022: the filing. The figures are in yen as filed.